SMS Pharmaceuticals Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹316 Cr +30.6% YoYSee revenue, profit and what management said. You are viewing Q1 FY27.
SP

SMS Pharmaceuticals Ltd

Q1 FY27Pharmaceuticals & Biotechnology

SMS Pharmaceuticals Q1 FY27: Revenue ₹207 Cr, PAT ₹20 Cr

Q1 FY27 investor presentation: what the company reported on revenue, margins and capex.

Revenue
₹207Cr
+5.6% YoY
−13% QoQ
Net profit
₹21Cr
+5% YoY
−36.4% QoQ
Margin
20%
0 pp YoY
+3 pp QoQ

Based on SMS Pharmaceuticals Ltd's Q1 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.

Price₹474
Market cap₹4.1K Cr
P/E40.5

The short version

Q1FY27 revenue from operations: ₹207 crore, up 6% YoY (Page 6, 5) - Q1FY27 EBITDA: ₹41 crore, up 4% YoY (Page 6) - Q1FY27 PAT: ₹20 crore, up 8% YoY (Page 6) - EPS for Q1FY27: ₹2.23 (Page 6) - Revenue from operations for FY26: ₹586.87 crore, up 13% YoY from FY25 (₹782.75 crore appears to be a typo or formatting issue; likely FY25 revenue was ₹782.75 crore as a base) (Page 27) - Gross margin steady at around 34-36% in Q1FY27 (Page 27) - Quarterly (Q1FY27) figures: - EBITDA: ₹41 crore, up 4% YoY - EBITDA Margin: 20%, sustained QoQ and YoY - PAT: ₹20 crore, up 8% YoY - PAT Margin: 10%, up slightly YoY - Year-on-Year (YoY)

From SMS Pharmaceuticals Ltd's Q1 FY27 earnings-call transcript · updated 25 Sept 2026.

Revenue & Sales Performance

  • Q1FY27 revenue from operations: ₹207 crore, up 6% YoY (Page 6, 5)
  • Q1FY27 EBITDA: ₹41 crore, up 4% YoY (Page 6)
  • Q1FY27 PAT: ₹20 crore, up 8% YoY (Page 6)
  • EPS for Q1FY27: ₹2.23 (Page 6)
  • Revenue from operations for FY26: ₹586.87 crore, up 13% YoY from FY25 (₹782.75 crore appears to be a typo or formatting issue; likely FY25 revenue was ₹782.75 crore as a base) (Page 27)
  • Gross margin steady at around 34-36% in Q1FY27 (Page 27)

2 more points from SMS Pharmaceuticals Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what SMS Pharmaceuticals Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

- Capex spend of ₹280 crore planned to be completed by FY27 (Page 25). - Capex oriented towards: • Capacity expansion for existing APIs. • Building capacities for new API pipeline. • Land acquisition in process for a greenfield project (Page 25). - Strategic focus: • Completed one Capex cycle in last 3-4 years; now focused on asset utilization to deliver best-in-class returns. • Current capex targeted to deliver returns in the high-teens range (Page 25).

2 more points from SMS Pharmaceuticals Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
2KRM Ayurveda
Rev 1Mar 1
3
Rev 1Mar 2
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what SMS Pharmaceuticals Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

See what SMS Pharmaceuticals Ltd said on order book & pipeline — free account, 30 seconds.

SMS Pharmaceuticals Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

SMS Pharmaceuticals Ltd Q1 FY27 results — key figures

SMS Pharmaceuticals Ltd Q1 FY27 reported results vs Q1 FY26, ₹ crore
₹ CrQ1 FY27Q1 FY26YoYQ4 FY26QoQ
Revenue207196+5.6%238-13%
Operating profit (EBITDA)4139+5.1%40+2.5%
Operating margin20%20%0 pp17%+3 pp
Profit before tax2724+12.5%270%
Net profit (PAT)2120+5%33-36.4%
EPS (₹)2.232.31-3.5%3.49-36.1%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹316 Cr, net profit ₹40 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Pharmaceuticals & Biotechnology this season

  • KRM Ayurveda (Q1 FY27)

    Total income for Q1 FY27: ₹3,286.55 Lakhs, +32.4% YoY . Key investor presentation takeaways from KRM Ayurveda Ltd's Q1 FY27 investor presentation — and how it r

  • Balaxi Pharma (Q1 FY27)

    Q1 FY27 Revenue: ₹80.68 crore, up 14.1% YoY from ₹70.74 crore in Q1 FY26 (Page 20). Key investor presentation takeaways from Balaxi Pharma's Q1 FY27 investor pr

  • Sanjivani Paranteral (Q1 FY27)

    Q1 FY27 consolidated revenue from operations: ₹238.39 Mn, up 33.8% YoY from ₹178.92 Mn in Q1 FY26 (Page 25). Key investor presentation takeaways from Sanjivani

  • Natural Capsules (Q1 FY27)

    Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

SMS Pharmaceuticals Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were SMS Pharmaceuticals Ltd Q1 FY27 results?

Q1FY27 revenue from operations: ₹207 crore, up 6% YoY (Page 6, 5) - Q1FY27 EBITDA: ₹41 crore, up 4% YoY (Page 6) - Q1FY27 PAT: ₹20 crore, up 8% YoY (Page 6) - EPS for Q1FY27: ₹2.23 (Page 6) - Revenue from operations for FY26: ₹586.87 crore, up 13% YoY from FY25 (₹782.75 crore appears to be a typo or formatting issue; likely FY25 revenue was ₹782.75 crore as a base) (Page 27) - Gross margin steady at around 34-36% in Q1FY27 (Page 27) - Quarterly (Q1FY27) figures: - EBITDA: ₹41 crore, up 4% YoY - EBITDA Margin: 20%, sustained QoQ and YoY - PAT: ₹20 crore, up 8% YoY - PAT Margin: 10%, up slightly YoY - Year-on-Year (YoY)

What is SMS Pharmaceuticals Ltd share price analysis?

SMS Pharmaceuticals Ltd currently shows a neutral. The stock trades at a P/E of 40.5 with a market cap of ₹4,148 Cr. Investors should review the full earnings analysis for detailed insights.

Is SMS Pharmaceuticals Ltd planning capital expenditure?

Capex spend of ₹280 crore planned to be completed by FY27 (Page 25).

Keep SMS Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.